Table 5.

Frequency of immunohistochemically defined breast tumor subtypes

HER2LuminalBasalP
HER23+2+, 1+, 02+, 1+, 0
ER and/or PgRPositive or negativePositiveNegative
Breast carcinomas of patients treated during breast tissue maturation, % (n)35.3 (6 of 17)58.8 (10 of 17)5.9 (1 of 17)NS
Case-control series, % (n)32.3 (11 of 34)55.9 (19 of 34)11.8 (4 of 34)
Breast carcinomas of patients treated after breast tissue maturation, % (n)12.5 (5 of 40)35 (14 of 40)52.5 (21 of 40)0.0001
Case-control series, % (n)21.2 (17 of 80)67.5 (54 of 80)11.3 (9 of 80)